ライフサイエンスコーパス: B-type natriuretic peptide

1 /=290 pg/mL) serum NT-proBNP (N-terminal pro-B-type natriuretic peptide).

2 endothelin-1, creatinine, and N-terminal pro-B-type natriuretic peptide.

3 r elevated baseline levels of N-terminal pro B-type natriuretic peptide.

4 measurement of the ventricular stress marker B-type natriuretic peptide.

5 tration, and 0.76 (0.60-0.93) for changes in B-type natriuretic peptide.

6 other risk factors including N-terminal pro-B-type natriuretic peptide.

7 or clinical variables and amino-terminal pro-B-type natriuretic peptide.

8 ore, left ventricular ejection fraction, and B-type natriuretic peptide.

9 en for C-reactive protein and N-terminal pro B-type natriuretic peptide.

10 ed preoperative end-systolic volume index or B-type natriuretic peptide.

11 ted by further adjustment for N-terminal pro-B-type natriuretic peptide.

12 f troponin T (0.05 ng/ml) and N-terminal pro-B-type natriuretic peptide (3,000 pg/ml).

13 ection fraction (ejection fraction=63+/-15%; B-type natriuretic peptide=431+/-366 pg/mL) was conducte

14 Secondary endpoints were quality of life, B-type natriuretic peptide, 6-min walk distance, and EF.

15 Patients with AF had higher N-terminal pro-B-type natriuretic peptide, aldosterone, endothelin-1, t

16 gene expression (atrial natriuretic peptide, B-type natriuretic peptide, alpha-skeletal actin), and c

17 Levels of N-terminal fragment of prohormone B-type natriuretic peptide also improved risk prediction

18 concentration, hemoglobin concentration, and B-type natriuretic peptide also significantly increased

19 after further adjustment for N-terminal pro-B-type natriuretic peptide and after exclusion of partic

20 lded modest improvement over a model without B-type natriuretic peptide and ankle-brachial index (C s

21 ts were similar to those with N-terminal pro-B-type natriuretic peptide and better than those with th

22 Patients had echocardiograms and measures of B-type natriuretic peptide and C-reactive protein before

23 Although significantly higher in group 2, B-type natriuretic peptide and echocardiography cardiac

24 Further adjustment for amino-terminal pro-B-type natriuretic peptide and estimated renal function

25 ial infarction (AMI) by using N-terminal pro-B-type natriuretic peptide and Global Registry of Acute

26 composed of the 3 biomarkers in addition to B-type natriuretic peptide and high-sensitivity C-reacti

27 ncludes age, biomarkers (N-terminal fragment B-type natriuretic peptide and high-sensitivity cardiac

28 Circulating N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac

29 Plasma concentrations of N- terminal pro-B-type natriuretic peptide and high-sensitivity cardiac

30 f either B-type natriuretic peptide (BNP) or B-type natriuretic peptide and its amino-terminal cleava

31 beyond what is obtained from N-terminal pro-B-type natriuretic peptide and peak stress left ventricu

32 istic=0.59); model 2: model 1+N-terminal pro-B-type natriuretic peptide and peak stress left ventricu

33 estimate the values of serum N-terminal pro-B-type natriuretic peptide and procalcitonin and the cha

34 rve 0.90 +/- 0.01), with no improvement when B-type natriuretic peptide and resting saturations were

35 ence of heterogeneity between N-terminal pro B-type natriuretic peptide and saxagliptin (P for intera

36 Serum B-type natriuretic peptide and troponin I were also asse

37 rdial wall stress and injury (N-terminal pro-B-type natriuretic peptide and troponin) versus enalapri

38 On backward elimination, B-type natriuretic peptide and urinary albumin-to-creati

39 use of natriuretic peptides (N-terminal pro-B type natriuretic peptide) and rest/exercise echocardio

40 PASP and potential mediators, including BNP (B-type natriuretic peptide) and endothelin-1.

41 -terminal pro-atrial natriuretic peptide and B-type natriuretic peptide) and lower blood concentratio

42 change in primary (change in N-terminal pro B-type natriuretic peptide) and secondary (change in lef

43 ed concentrations of glucose, N-terminal pro-B type natriuretic peptide, and cystatin C.

44 nt for clinical risk factors, N-terminal pro-B-type natriuretic peptide, and a wide range of echocard

45 le combination of standard CVD risk factors, B-type natriuretic peptide, and ankle-brachial index (mo

46 line body mass index, height, N-terminal pro-B-type natriuretic peptide, and cystatin C, with longer

47 based on cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and d-dimer levels at baseli

48 Cardiac troponin I, N-terminal pro-B-type natriuretic peptide, and d-dimer levels were meas

49 high-sensitivity troponin T, N-terminal pro-B-type natriuretic peptide, and high-sensitivity C-react

50 nsitivity C-reactive protein, N-terminal pro-B-type natriuretic peptide, and high-sensitivity cardiac

51 or conventional risk markers, N-terminal pro-B-type natriuretic peptide, and hs-TnT, hs-TnI levels in

52 rular filtration rate, higher N-terminal pro-B-type natriuretic peptide, and ischemic cause of heart

53 of angiotensin inhibition therapy, elevated B-type natriuretic peptide, and larger left ventricular

54 n, d-dimer, homoarginine, and N-terminal pro B-type natriuretic peptide, and lower levels of low-dens

55 rmonal activity (aldosterone-to-renin ratio, B-type natriuretic peptide, and N-terminal proatrial nat

56 s to the multivariable model were H/M, LVEF, B-type natriuretic peptide, and NYHA functional class.

57 mass index, electrocardiographic parameters, B-type natriuretic peptide, and other biochemical and he

58 ctional class or Ross class), N-terminal pro-B-type natriuretic peptide, and quality of life (QOL) we

59 entricular ejection fraction, N-terminal pro-B-type natriuretic peptide, and ST2.

60 cle ergometry, measurement of N-terminal pro-B-type natriuretic peptide, and subjective health assess

61 Ultrasensitive troponin I, N-terminal pro-B-type natriuretic peptide, and the interleukin family m

62 action, pericardial effusion, N-terminal pro-B-type natriuretic peptide, and troponin T.

63 re significantly older, had higher levels of B-type natriuretic peptide, and were predominantly hyper

64 sensitivity troponin and N-terminal fragment B-type natriuretic peptide], and clinical history of pri

65 cardiac troponins, NT-proBNP [N-terminal pro-B-type natriuretic peptide], and galectin-3).

66 oncentrations, hemoglobin concentration, and B-type natriuretic peptide are reliable alternatives to

67 tic resonance imaging and BNP/N-terminal pro-B-type natriuretic peptide, are emerging as promising in

68 or predicting 90-day mortality compared with B-type natriuretic peptide (area under the curve: 0.674

69 rement of soluble ST2 and amino-terminal pro-B-type natriuretic peptide at 12 hours added value to Ca

70 We measured B-type natriuretic peptide at hospital admission in acut

71 N-terminal pro B-type natriuretic peptide (available in 2632 patients)

72 natriuretic peptides, such as N-terminal pro-B-type natriuretic peptide/B-type natriuretic peptide, t

73 sponse to cardiac stress, the heart secretes B-type natriuretic peptide (BNP(1-32)) and amino-termina

74 cted to define the association between serum B-type natriuretic peptide (BNP) activation and survival

75 safety and efficacy of 8 weeks of chronic SC B-type natriuretic peptide (BNP) administration in human

76 rial, we determined whether plasma levels of B-type natriuretic peptide (BNP) and cardiac troponin I

77 quantified cardiac hemodynamic stress using B-type natriuretic peptide (BNP) and cardiomyocyte damag

78 tracellular cGMP production is stimulated by B-type natriuretic peptide (BNP) and degraded by phospho

79 las Heart Study underwent measurements of 1) B-type natriuretic peptide (BNP) and N-terminal pro-B-ty

80 dy was to determine the relationship between B-type natriuretic peptide (BNP) and survival in patient

81 Measurement of B-type natriuretic peptide (BNP) and the cardiological e

82 ective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of ranol

83 designed to monitor daily concentrations of B-type natriuretic peptide (BNP) and to determine how th

84 ata on the prognostic value of postoperative B-type natriuretic peptide (BNP) are scarce.

85 An elevated B-type natriuretic peptide (BNP) concentration alone was

86 Cardiac troponin and B-type natriuretic peptide (BNP) concentrations are asso

87 h-sensitivity C-reactive protein (hsCRP) and B-type natriuretic peptide (BNP) concentrations at 72 h

88 Lower plasma B-type natriuretic peptide (BNP) concentrations in obese

89 We further hypothesized that exogenous B-type natriuretic peptide (BNP) could rescue an impaire

90 mpanied by anorexia and increased release of B-type natriuretic peptide (BNP) from ventricular cardio

91 B-type natriuretic peptide (BNP) has been proposed as a

92 B-type natriuretic peptide (BNP) has BP-lowering, antifi

93 eptides atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in heart tissue may als

94 sought to determine the prognostic value of B-type natriuretic peptide (BNP) in patients with heart

95 secrete atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) in response to mechanic

96 B-type natriuretic peptide (BNP) is a guanylyl cyclase A

97 B-type natriuretic peptide (BNP) is a useful prognostic

98 Plasma B-type natriuretic peptide (BNP) is abnormally elevated

99 Numerous experimental studies suggest that B-type natriuretic peptide (BNP) is cardioprotective; ho

100 correlation between TMAO concentrations and B-type natriuretic peptide (BNP) levels (r = 0.23; p < 0

101 herefore sought to examine whether admission B-type natriuretic peptide (BNP) levels predict the deve

102 Studies suggesting that B-type natriuretic peptide (BNP) may predict outcomes of

103 ble reduction in the concentration of either B-type natriuretic peptide (BNP) or B-type natriuretic p

104 Serum B-type natriuretic peptide (BNP) plays an important role

105 nators in serum by LR were troponin I (TnI), B-type natriuretic peptide (BNP), and creatine kinase-MB

106 ardiograph, a decreasing or normalization of B-type natriuretic peptide (BNP), and hemodynamics with

107 Circulating RBP4, TTR, B-type natriuretic peptide (BNP), and troponin I (TnI) c

108 B-type natriuretic peptide (BNP), C-reactive protein (CR

109 (NPs), atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), have central roles in

110 We have reported that pro-B-type natriuretic peptide (BNP)-1-108 circulates and is

111 uding left ventricular ejection fraction and b-type natriuretic peptide (BNP).

112 ine C34:4, has a diagnostic value similar to B-type natriuretic peptide (BNP).

113 n and fibrinogen), neurohormonal activation (B-type natriuretic peptide [BNP] and N-terminal proatria

114 (Heart Failure [HF] Assessment with B-type Natriuretic Peptide [BNP] In the Home [HABIT]; NC

115 sensitivity cardiac troponin T [hs-cTnT] or B-type natriuretic peptide [BNP]).

116 for mortality in addition to N-terminal pro-B-type natriuretic peptide (C-statistic: 0.59 versus 0.6

117 in T, creatine kinase, myoglobin, N-terminal B-type natriuretic peptide, C-reactive protein, and leuk

118 n, lower expression of cardiac stress genes (B-type natriuretic peptide, collagen gene expression), l

119 (48 versus 40), higher median N-terminal pro-B-type natriuretic peptide concentration (403 versus 320

120 (-5.1 to -0.8, p=0.0070), and N-terminal pro B-type natriuretic peptide concentration in plasma -970

121 as associated with NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentration (0.57 on a log

122 the kallikrein B locus were associated with B-type natriuretic peptide concentrations in blacks.

123 After extensive adjustments, N-terminal pro-B-type natriuretic peptide concentrations predicted ICU

124 cretoneurin measurements, and N-terminal pro-B-type natriuretic peptide did not improve patient class

125 ty of disease as indicated by N-terminal pro B-type natriuretic peptide, E/E', and left atrial volume

126 ent after adjustment for age, N-terminal pro-B-type natriuretic peptide, ejection fraction, E/E', and

127 rotein, IL-6, troponin T, and N-terminal pro-B-type natriuretic peptide, elevated soluble gp130 (fift

128 Combined assessment of sFlt-1 and B-type natriuretic peptide exhibited high predictive acc

129 he initial studies showing the usefulness of B-type natriuretic peptide for aiding in heart failure d

130 /- 130 m; P<0.001), and decreased N-terminal B-type natriuretic peptide (from 2322 +/- 1234 pg/mL to

131 6.2% to 27.1+/-6.6%; P=0.23), N-terminal pro B-type natriuretic peptide (from 3322+/-3411 to 3672+/-5

132 ; P=0.001), and a decrease in N-terminal pro B-type natriuretic peptide (from 3672+/-5165 to 1488+/-1

133 Exercise testing, echocardiography, B-type natriuretic peptide, functional health assessment

134 le ST2, >/= 500 ng/mL and amino-terminal pro-B-type natriuretic peptide, >/= 4,500 ng/L) had higher 3

135 In just 10 years, B-type natriuretic peptide has gone from being an unknow

136 n time, left atrium dimension, E/e', and pro B-type natriuretic peptide (hazard ratio, 1.05; 95% conf

137 In backward elimination analyses, higher log-B-type natriuretic peptide (hazard ratio, 1.39 per 1-SD

138 0.84 to 0.99; p = 0.027) and N-terminal pro-B-type natriuretic peptide (hazard ratio: 0.98; 95% conf

139 on functional class [WHO-FC], N-terminal-pro-B-type natriuretic peptide, hemodynamics) and lung-trans

140 djustment for clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive

141 that included clinical prognostic variables, B-type natriuretic peptide, high-sensitivity C-reactive

142 ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac tro

143 ECG, coronary artery calcium, N-terminal pro B-type natriuretic peptide, high-sensitivity cardiac tro

144 Levels of N-terminal fragment B-type natriuretic peptide, high-sensitivity cardiac tro

145 sponse to LCZ696 for lowering N-terminal pro B-type natriuretic peptide; however, left atrial volume

146 after adjustment for clinical variables and B-type natriuretic peptide (HR: 1.23; 95% CI: 1.04 to 1.

147 Plasma levels of B-type natriuretic peptide, hs-TnI (high-sensitivity tro

148 luding clinical variables and N-terminal pro-B-type natriuretic peptide) improved discrimination (C-s

149 ivity C-reactive protein, and N-terminal pro-B-type natriuretic peptide in 9698 participants aged 54

150 ssment (11 risk factors) plus N-terminal pro-B-type natriuretic peptide in terms of discrimination, c

151 When including B-type natriuretic peptide in the model, only a decreasi

152 11% vs. 55 +/- 10%; p < 0.001; n = 259), and B-type natriuretic peptide increased (median [interquart

153 eight loss, reduction in amino terminal, pro B-type natriuretic peptide, increased plasma renin activ

154 ical variables (including log N-terminal pro-B-type natriuretic peptide) indicated that increased LV

155 , matrix metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40

156 , matrix metalloproteinase-3, N-terminal pro-B-type natriuretic peptide, interleukin-6, soluble CD40

157 B-Type natriuretic peptide is a cardiac hormone with vas

158 Cardiovascular parameters (N-terminal pro-B-type natriuretic peptide, left and right ventricular f

159 eraged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 da

160 thoracic echocardiography and measurement of B-type natriuretic peptide level from venous blood sampl

161 se (CVD), a 10-year risk of CVD < 20%, and a B-type natriuretic peptide level greater than their gend

162 of 25% [IQR, 19%-33%]; median N-terminal pro-B-type natriuretic peptide level of 2049 pg/mL [IQR, 105

163 variable HR for a 1-SD higher N-terminal pro-B-type natriuretic peptide level, 1.15; 95% CI, 1.04-1.2

164 ge, ejection fraction, plasma N-terminal pro-B-type natriuretic peptide level, and prior hospitalizat

165 level, troponin T level, log N-terminal pro-B-type natriuretic peptide level, fibroblast growth fact

166 water indexed for ideal body weight, plasma B-type natriuretic peptide level, hemoglobin, and plasma

167 Age, B-type natriuretic peptide level, renal dysfunction, 24-

168 al therapy but fewer comorbidities and lower B-type natriuretic peptide level.

169 N-Terminal pro-B type natriuretic peptide levels were below the level c

170 p > 0.001), and higher median N-terminal pro-B-type natriuretic peptide levels (3,495 vs. 1,730 ng/dl

171 CI, 1.55-2.44), and abnormal N-terminal pro-B-type natriuretic peptide levels (defined as >400 pg/mL

172 currence rates in addition to an increase in B-type natriuretic peptide levels (P=0.01), C-reactive p

173 Serum N-terminal pro-B-type natriuretic peptide levels and certain hemodynami

174 AF patients had higher B-type natriuretic peptide levels and ejection fraction

175 Group 2 patients also had higher B-type natriuretic peptide levels and lower scores in 3

176 B-type natriuretic peptide levels correlate with AF burd

177 N-terminal pro-B-type natriuretic peptide levels decreased similarly in

178 In contrast, B-type natriuretic peptide levels did not differ by rs50

179 B-type natriuretic peptide levels increased over time an

180 hospitalized with acute coronary syndromes, B-type natriuretic peptide levels measured at admission

181 ad NT-proBNP levels of 1000 pg/mL or more or B-type natriuretic peptide levels of 250 pg/mL or more,

182 both), in contrast to plasma N-terminal pro-B-type natriuretic peptide levels that were not (area un

183 N-terminal pro-B-type natriuretic peptide levels were abnormal in 97.4%

184 ung ultrasound, echocardiography, and plasma B-type natriuretic peptide levels were determined before

185 dy and troponin I and N terminal fragment of B-type natriuretic peptide levels were determined.

186 B-type natriuretic peptide levels were higher in acute k

187 B-type natriuretic peptide levels were measured at rest

188 In contrast, N-terminal pro-B-type natriuretic peptide levels were not associated wi

189 worse quality of life, higher N-terminal pro-B-type natriuretic peptide levels, and a poorer prognosi

190 ntricular function, decreased N-terminal pro B-type natriuretic peptide levels, and better exercise c

191 minute walk distances, higher N-terminal pro-B-type natriuretic peptide levels, and the presence of r

192 In Cox Proportional Hazard analyses, B-type natriuretic peptide levels, C-reactive protein le

193 ricular reverse remodeling, MR severity, and B-type natriuretic peptide levels, compared with CABG al

194 with worse intracardiac hemodynamics, higher B-type natriuretic peptide levels, lower exercise capaci

195 k factors (N-terminal fragment of prohormone B-type natriuretic peptide levels, von Willebrand factor

196 ventricular ejection fraction, or N-terminal B-type natriuretic peptide levels.

197 mL]; P<0.0001), despite lower N-terminal pro-B-type natriuretic peptide levels.

198 schemic HF, atrial fibrillation, and similar B-type natriuretic peptide levels.

199 umin had significantly higher N-terminal pro-B-type natriuretic peptide levels; in addition, early ri

200 uble receptors and NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) levels were important across

201 Although LCZ696 reduced N-terminal pro B-type natriuretic peptide, levels of the other 4 biomar

202 ss, mitral regurgitation, and N-terminal pro-B-type natriuretic peptide, lower TAPSE, and assignment

203 mination in analyses of interactions between B-type natriuretic peptide, LVEF, and H/M.

204 N-terminal pro-B-type natriuretic peptide (median: 11.6 pmol/l [interqu

205 d glomerular filtration rate, N-terminal pro-B-type natriuretic peptide, mineralocorticoid receptor a

206 s strong as that obtained for N-terminal pro-B-type natriuretic peptide (multivariable HR for a 1-SD

207 oplasmin, nitrotyrosine-bound ceruloplasmin, B-type natriuretic peptide, norepinephrine, and high-sen

208 Ceruloplasmin, B-type natriuretic peptide, norepinephrine, and high-sen

209 c peptide (BNP(1-32)) and amino-terminal pro-B-type natriuretic peptide (NT-proBNP(1-76)) after intra

210 After further adjusting for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and C-reactive pr

211 N-terminal pro-B-type natriuretic peptide (NT-proBNP) and circumferenti

212 ce of elevated troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and their associa

213 nship with N-terminal fragment of prohormone B-type natriuretic peptide (NT-proBNP) are unknown.

214 Increased N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration pre

215 he prognostic value of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) for death and car

216 Although N-terminal pro-B-type natriuretic peptide (NT-proBNP) has a strong rela

217 was to determine the value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in adults with co

218 whether serial measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in community-dwel

219 ssess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with

220 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a strong predi

221 Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated wit

222 assess whether a reduction in N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated wit

223 Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) is considered a m

224 ided by concentrations of amino-terminal pro-B-type natriuretic peptide (NT-proBNP) is superior to st

225 ular mortality over and above N-terminal pro-B-type natriuretic peptide (NT-proBNP) level in older ad

226 s, and percent reduction in serum N terminal B-type natriuretic peptide (NT-proBNP) level-and relief

227 on (P < .001); and had higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels (P < .001)

228 ronolactone and usual care on N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels compared w

229 Therapy guided by N-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels may improv

230 ST2 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were measu

231 -minute walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and healt

232 lysis on those with available N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.

233 oponin T (cTnT), and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) on cardiovascular

234 tivity troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) strongly predict

235 We measured plasma GDF-15, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and C-reactive p

236 nsitive troponin T (cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), and the subseque

237 ity C-reactive protein (CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth different

238 We studied the association of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitive t

239 ostic value of the biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity

240 edian percent change in serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity

241 ost important biomarkers were N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity

242 or age, sex, body mass index, N-terminal pro-B-type natriuretic peptide (NT-proBNP), renal function,

243 We measured N-terminal pro-B-type natriuretic peptide (NT-proBNP), total testostero

244 ined whether repeated measurements of NT-pro-B-type natriuretic peptide (NT-proBNP), troponin T (Trop

245 igate the association between N-terminal pro-B-type natriuretic peptide (NT-proBNP), which is a marke

246 To determine whether an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment

247 2 in log-transformed level of N-terminal pro-B-type natriuretic peptide (NT-proBNP).

248 ere blood pressure and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP).

249 myocardial band (CK-MB), and N-terminal pro-B-type natriuretic peptide (NT-proBNP).

250 diabetic patients selected by N-terminal pro-B-type natriuretic peptide (NT-proBNP).

251 ivity troponin T (hs-TnT) and N-terminal pro B-type natriuretic peptide (NT-proBNP).

252 markers troponin-T (cTnT) and N-terminal pro-B-type natriuretic peptide (NT-ProBNP).

253 natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP); and 2) body fat

254 ysfunction: C-reactive protein (CRP); NT-pro-B-type natriuretic peptide (NT-proBNP); troponin I; matr

255 tion [LVEF] 26 +/- 6%, median N-terminal pro-B-type natriuretic peptide [NT-proBNP] 1,158 pg/ml), the

256 Risk Evaluation (EuroSCORE), N-terminal pro-B-type natriuretic peptide (NTproBNP), and high-sensitiv

257 Early changes in N-terminal pro-B-type natriuretic peptide or high-sensitivity cardiac t

258 Compared with B-type natriuretic peptide or troponin, MR-proADM was su

259 porated LA volume, NT-proBNP (N-terminal pro-B-type natriuretic peptide), or left ventricular E/e' (a

260 Association functional class (p < 0.01) and B-type natriuretic peptide (p < 0.01).

261 es showed excellent discriminative power for B-type natriuretic peptide (p = 0.001; 95% CI, 0.99-1.00

262 tein cholesterol (p = 0.005), N-terminal pro-B-type natriuretic peptide (p = 0.004), and left ventric

263 ion improved Minnesota score (p = 0.019) and B-type natriuretic peptide (p = 0.045) and showed nonsig

264 k stress PLSR (P<0.0001), and N-terminal pro-B-type natriuretic peptide (P<0.0001).

265 xcursion) (P=0.002), (2) high N-terminal pro-B-type natriuretic peptide (P=0.085), (3) systemic (P=0.

266 walk distance, and NT-proBNP (N-terminal pro-B-type natriuretic peptide; P<0.05 for all).

267 nd men, as well as in the total cohort, were B-type natriuretic peptide, peak oxygen consumption by c

268 le risk model assessing 4 clinical variables-B-type natriuretic peptide, pkVO2, NYHA, and angiotensin

269 The ANP and B-type natriuretic peptide play an important role in car

270 B-type natriuretic peptide plus hs-cTnT together perform

271 his study was to investigate circulating pro-B-type natriuretic peptide (proBNP(1-108)) in the genera

272 N-terminal pro-B-type natriuretic peptide, procalcitonin, and waveform

273 sults for soluble ST2 and amino-terminal pro-B-type natriuretic peptide provides early risk assessmen

274 Left ventricular ejection fraction, B-type natriuretic peptide, pulse-wave velocity, and pul

275 n was greatest in the highest N-terminal pro B-type natriuretic peptide quartile (2.1%).

276 ute kidney injury increased in parallel with B-type natriuretic peptide quartiles (5%, 9%, 15%, and 2

277 ly with hs-TnT (r = 0.44) and N-terminal pro-B-type natriuretic peptide (r = 0.39) but only weakly wi

278 h higher myeloperoxidase (r=0.42, P<0.0001), B-type natriuretic peptide (r=0.25, P=0.001), and asymme

279 systolic volume index, MR volume, and plasma B-type natriuretic peptide reduction of 22.2 mL/m(2), 28

280 phy, cardiomyocyte death, and N-terminal pro B-type natriuretic peptide release; all are classical ha

281 0; P<0.0001), log-transformed N-terminal pro B-type natriuretic peptides (RR per SD 1.27; P<0.0001),

282 nation of soluble ST2 and amino-terminal pro-B-type natriuretic peptide showed excellent discriminati

283 itivity C-reactive protein, myeloperoxidase, B-type natriuretic peptide, soluble fms-like tyrosine ki

284 ficantly from "no sepsis" for N-terminal pro-B-type natriuretic peptide, systemic vascular resistance

285 ing study), high-sensitivity troponin I, and B-type natriuretic peptide ( Table 1 ).

286 Patients with NF/LG had significantly lower B-type natriuretic peptide than those with LF/HG and LF/

287 culating levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) than HF patients without AF.

288 x, (4) circulating NT-proBNP (N-terminal pro-B-type natriuretic peptide), TNF-alpha, IL-6, IL-12, IL-

289 rement of soluble ST2 and amino-terminal pro-B-type natriuretic peptide to clinical parameters for ri

290 F included the combination of N-terminal pro-B-type natriuretic peptide, troponin-T, and urinary albu

291 ces were found between any 2 time points for B-type natriuretic peptide, tumor necrosis factor-alpha,

292 alue of blood volume contraction indices and B-type natriuretic peptide variations.

293 related with torsion, strain, N-terminal pro-B-type natriuretic peptide, vascular endothelial growth

294 ration at rest was 85.1 +/- 7.8%, and median B-type natriuretic peptide was 55.4 ng/L.

295 Elevated N-terminal pro-B-type natriuretic peptide was also associated with an i

296 s; in addition, early rise in N-terminal pro-B-type natriuretic peptide was associated with a better

297 When B-type natriuretic peptide was evaluated, in terms of ca

298 Baseline N-terminal pro B-type natriuretic peptide was measured in 12 301 patien

299 ular function, end-systolic volume index and B-type natriuretic peptide were most strongly associated

300 V, RVESRI, and log NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) were retained (chi(2), 62.2;